The Wegovy pill in brief: a once-daily 25 mg tablet
The "Wegovy pill" is Novo Nordisk's once-daily oral form of semaglutide, developed for weight management and taken as a tablet rather than a weekly injection[1]. The MHRA licensed it on 11 June 2026 as the first oral GLP-1 medicine for weight management in the UK[3]. The maintenance (target) dose is 25 mg once daily[1][2] — but nobody starts there. As with every GLP-1 medicine, the dose is climbed in steps.
The dose ladder: 1.5 mg up to 25 mg
According to UK reporting of the MHRA licence, the Wegovy tablet is titrated once daily through four levels — 1.5 mg, 4 mg, 9 mg and 25 mg — with a minimum of one month at each dose before moving up[3]. Starting low and rising slowly is standard practice for GLP-1 medicines: the most common side effects are gastrointestinal, and in the approval-supporting trial they were mostly mild-to-moderate and eased over time[6].
| Step | Once-daily dose | Minimum time before the next step |
|---|---|---|
| Start | 1.5 mg | At least one month |
| 2 | 4 mg | At least one month |
| 3 | 9 mg | At least one month |
| Maintenance | 25 mg | — |
The 1.5 mg and 4 mg tablets are stepping stones, not destinations; 25 mg is the maintenance dose. "At least one month" is a minimum — a prescriber can hold a dose longer, or step back down, if side effects are a problem. Patients never adjust the dose themselves.
Switching from the Wegovy injection
Some people come to the tablet having already used the injectable form of Wegovy. UK guidance on the licence states that patients on the 2.4 mg once-weekly semaglutide injection can be transitioned directly to the 25 mg once-daily tablet[3] — without starting again at the bottom of the ladder. It remains a prescriber's decision. How the two routes compare is covered on our Wegovy pill vs injection page.
Don't confuse the pill's doses with Rybelsus or the trial doses
Three sets of milligram numbers get attached to oral semaglutide, and mixing them up is a common error:
- The Wegovy pill (weight management): 1.5 mg → 4 mg → 9 mg → 25 mg once daily[3].
- Rybelsus (type 2 diabetes): a separate, lower-dose oral semaglutide in 3 mg, 7 mg and 14 mg tablets[4] — the same molecule delivered the same way, but a distinct product with a different ladder and licensed use.
- The research doses: the OASIS obesity trials tested 25 mg and 50 mg, and an earlier 50 mg read-out reported an average weight change of about −15.1% versus −2.4% on placebo[5]. The approved tablet is 25 mg, not 50 mg.
How to take the Wegovy pill: the empty-stomach rules
The instruction is one tablet a day, but the timing around it is unusually strict — for good reason (below). UK guidance on the licence sets it out as follows[3]:
- Once daily, first thing in the morning, on an empty stomach after fasting overnight — at least 8 hours without food[3].
- With plain water only. MHRA messaging describes taking it with a sip of water[3]; the established labelling for oral semaglutide specifies no more than about 120 mL (roughly four ounces)[4]. Either way: a small amount of plain water, nothing else.
- Then wait at least 30 minutes before eating, drinking anything else, or taking any other medicine[3].
The tablet should be swallowed whole — not crushed, cut, chewed or dissolved, as breaking it up interferes with absorption.
Oral semaglutide is not absorbed like an ordinary tablet: how much of the dose reaches the body depends heavily on taking it exactly as directed. That is why the labelling is so specific — an empty stomach, only a small amount of plain water, and no food, other drinks or other medicines for at least 30 minutes afterwards[4]. Taking it with food, with more water than allowed, or alongside other tablets too soon means less of the dose is absorbed. Get the routine wrong and you are lowering the effective dose, not just bending a rule.
Why taking it correctly matters: adherence and results
Because absorption depends so heavily on the daily routine, consistency is part of the treatment. The approval-supporting OASIS 4 trial of the 25 mg tablet showed this clearly. Measured as the effect if the medicine is taken fully as directed, average weight loss was about −16.6% versus −2.7% on placebo[1]. Measured across everyone regardless of how well they stuck to it, the average was about −13.6% versus −2.4%[2]. Around 76% of people on the tablet lost at least 5% of their body weight versus 31% on placebo[2], and Novo Nordisk reports roughly one in three reached at least 20%[1]. The gap between those two headline figures — taken perfectly versus taken as people really manage — is the case for getting the daily habit right.
Side effects during titration, and how to report them
Because the dose is climbed rather than started high, the toughest patch is usually the escalation phase. In OASIS 4, gastrointestinal effects — nausea, diarrhoea, vomiting, constipation and stomach pain among them — were reported by about 74% of people on the tablet versus 42% on placebo, mostly mild-to-moderate and easing over time[6]. Discontinuation because of side effects was low and close to placebo, at about 7% versus 6%[6]. Our Wegovy pill side effects page goes through the full list and who should not take it.
If you experience side effects from any medicine, report them through the MHRA Yellow Card scheme[7] and speak to your GP or pharmacist. Severe, persistent stomach pain, signs of dehydration from vomiting or diarrhoea, or any symptom that worries you are reasons to get medical advice rather than keep pushing on with the dose.
Storage and missed doses
The definitive storage and missed-dose instructions belong to the patient information leaflet and your pharmacist, not a website. As a baseline, keep tablets in their original packaging, at room temperature away from heat and moisture, and out of children's reach. Launch coverage reported that, unlike some injectable treatments, the tablet does not need refrigeration[8] — though the conditions on the box are what count. If a dose is missed, do not double up unless a healthcare professional tells you to.
Getting it in the UK
The Wegovy pill is a prescription-only medicine. Since the June 2026 MHRA licence it can be prescribed privately following a proper consultation, but it is not funded on the NHS; NHS access would require a separate NICE technology appraisal, which had not concluded when the medicine was licensed[3]. NICE has already restricted NHS use of injectable semaglutide to defined patient groups rather than open access[9] — a fair indication of how the pill may be handled if recommended, though nothing is confirmed yet.
The licensed use is broadly for adults living with obesity, or with overweight alongside a weight-related health condition, as an add-on to a reduced-calorie diet and more physical activity[1][2]. Whether that applies to a given person is for a prescriber to decide, and anyone who could become pregnant should discuss it with their prescriber, as semaglutide is not for use in pregnancy. We do not sell, supply or recommend any provider; lawful UK supply runs through GPhC-registered pharmacies against a valid prescription only.
Frequently asked questions
How do you take the Wegovy pill?
One tablet a day, swallowed whole, first thing on an empty stomach after fasting overnight (at least 8 hours), with plain water only — then wait at least 30 minutes before eating, drinking anything else, or taking any other medicine[3]. These rules are what allow the semaglutide to be absorbed.
What is the maximum dose of the Wegovy pill?
Do you take the Wegovy pill on an empty stomach?
Yes — first thing, after fasting overnight, with only plain water, then a wait of at least 30 minutes before anything else[3]. Those timing rules match the established labelling for oral semaglutide[4], and following them exactly is what allows the medicine to be absorbed properly — taking it with food, too much water, or other tablets too soon lowers how much of the dose gets in.
Is the Wegovy pill the same as Rybelsus?
Both are oral semaglutide, but they are different products. Rybelsus (3 mg, 7 mg, 14 mg) is licensed for type 2 diabetes[4]; the Wegovy pill is a higher-dose oral semaglutide (up to 25 mg) for weight management. Their milligram numbers are not interchangeable.
Is the Wegovy pill better than the injection?
It is not a matter of better or worse — both contain the same molecule. The pill is taken by mouth daily with strict timing; the injection is given weekly under the skin. Which route suits someone is a prescriber's decision, and people on the 2.4 mg weekly injection can switch directly to the 25 mg daily tablet[3]. See our pill vs injection page.
What should I do if I miss a dose?
Follow the patient information leaflet, or ask your prescriber or pharmacist. As a general rule for any once-daily medicine, do not take extra tablets to make up for a missed dose unless a healthcare professional tells you to.
References
- Novo Nordisk. Wegovy (oral semaglutide 25 mg) regulatory approval — company announcement: first oral GLP-1 for weight management; OASIS 4 trial-product weight loss; proportion reaching at least 20%. novonordisk.com
- Novo Nordisk news release, via PR Newswire. "FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults" — 25 mg maintenance dose; OASIS 4 treatment-policy weight loss; proportion losing at least 5%. December 2025. (Source cited by name; not linked, per this site's external-links policy.)
- The Pharmaceutical Journal. "MHRA approves semaglutide oral tablets for weight loss" — UK titration ladder; empty-stomach administration rules; switch from the once-weekly injection; UK NHS status. June 2026. (Source cited by name; not linked, per this site's external-links policy.)
- US Food and Drug Administration. Rybelsus (oral semaglutide) prescribing information — 3 mg, 7 mg and 14 mg strengths and the oral-semaglutide administration rules (empty stomach, plain water no more than 120 mL, wait at least 30 minutes). accessdata.fda.gov
- The Lancet. OASIS 1 — oral semaglutide 50 mg in adults with overweight or obesity (2023). thelancet.com
- American College of Cardiology. OASIS 4 journal scan — oral semaglutide 25 mg: gastrointestinal adverse events and discontinuation rates. September 2025. (Source cited by name; not linked, per this site's external-links policy.)
- MHRA. Yellow Card scheme — report a side effect. yellowcard.mhra.gov.uk
- ABC News. Coverage of the US FDA approval of the Wegovy pill — reported that the tablet does not require refrigeration. December 2025. (Single source, cited by name; not linked, per this site's external-links policy.)
- NICE. Technology appraisal TA875 — semaglutide (injectable) for managing overweight and obesity (context for the pill's likely NHS route). nice.org.uk